Brind.
  1. AbbVie's Humira is facing steep competition from Omvoh in the market.
  2. Declining sales of Humira due to biosimilar erosion.

Eight Humira Biosimilars Launch, Accelerating Market Competition

1 report, 1 independent Updated Oct 8
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Eight biosimilars for HUMIRA were launched on October 8, 2026, increasing competition in the market. The dispensing of these biosimilars is determined by payer formularies and interchangeability rules. Reports note that biosimilars are equally safe and cut costs.

From pharmacytimes.com

Why it matters

Some supportBrind's analysis of the reports

The launch accelerates the erosion of HUMIRA's sales, which is a core asset for AbbVie. Increased biosimilar supply could drive down drug costs, impacting Medicare's budget.

AbbVie's HUMIRA sales have been declining due to biosimilar erosion, and the drug is already facing steep competition from Omvoh.

From pharmacytimes.com

Who's involved

  • HUMIRAThe subject of the biosimilar launches, facing increased competition.
  • AbbVieThe pharmaceutical company that manages HUMIRA and is navigating biosimilar competition.
  • AlvotechA biotechnology company developing a biosimilar product intended to compete directly with HUMIRA.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • AbbVieSpeculative

    AbbVie could see its revenue stream eroded due to increased competition for HUMIRA.

  • HUMIRASpeculative

    HUMIRA may lose market share and pricing power due to the eight new biosimilars.

  • MedicareSpeculative

    Medicare could face changes in budget due to increased biosimilar supply driving down drug costs.

Keep exploring

Part of

Declining sales of Humira due to biosimilar erosion. All 2 developments

Within AbbVie's Humira is facing steep competition from Omvoh in the market.

The entities involved

Coverage

Newest first; wire copies grouped